Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914535 · ClinicalTrials.gov registry record · Phase 3
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
A Phase 3 study of Ulcerative Colitis, sponsored by Alfasigma S.p.A..
- Active
- Registry status
- Phase 3
- Development phase
- 1,173
- Enrollment target
- 20
- Study locations
NCT02914535 is a Phase 3 study of Ulcerative Colitis that is active but no longer recruiting, run by Alfasigma S.p.A.. The registered enrollment target is 1,173 participants, below the 2,048-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02914535, a Phase 3 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Alfasigma S.p.A..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,173 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Filgotinib
Study Locations (20)
Florida
- UF Clinical Research Center - Gainesville
- Florida Research Institute - Lakewood Rch
- University of Miami Crohn's and Colitis Center - Miami
- Cordova Research Institute - Miami
- Gastroenterology Group of Naples - Naples
- Advanced Medical Research Center - Port Orange
- Tampa General Hospital - Tampa
- Florida Medical Clinic, P.A - Zephyrhills
Georgia
- Gastroenterology Associates Of Central Georgia, LLC - Macon
- Gastrointestinal Specialists of Georgia - Marietta
- Atlanta Gastroenterology Specialist, PC - Suwanee
California
- VA Long Beach Healthcare System - Long Beach
- Cedars Sinai Medical Center - Los Angeles
Alabama
- Digestive Health Specialists Of The Southeast - Dothan
Arizona
- Mayo Clinic Arizona - Scottsdale
Colorado
- South Denver Gastroenterology, PC - Lone Tree
Connecticut
- Connecticut GI PC-Research Division - Farmington
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,173 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914535
The ClinicalTrials.gov registry entry for NCT02914535 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,173 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (43% lower). The listed sponsor is Alfasigma S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02914535 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Georgia, California.
Frequently Asked Questions
What is clinical trial NCT02914535 about?
NCT02914535 is a clinical study titled "Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis". The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
What is the current status of trial NCT02914535?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,173 participants. The study started on 2017-02-23. Estimated completion is 2026-09.
What conditions does trial NCT02914535 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT02914535?
The interventions under investigation include: Placebo (DRUG), Filgotinib (DRUG).
Who is sponsoring clinical trial NCT02914535?
This trial is sponsored by Alfasigma S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914535 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.